Mumbai: Marksans Pharma Limited has announced that its manufacturing facility located at Plot A-1, Phase 1-A, Verna Industrial Estate, Verna, Goa has been approved by Australian TGA for manufacture of pharmaceutical formulations in Solid Dosage Forms of Tablets and hard Capsules for Australian markets.
The products will be manufactured at the above facility in Goa India and marketed & distributed in Australian markets through the Company’s subsidiary Nova Pharmaceuticals Australasia Pty Ltd.
In August 2024, the US Food and Drug Administration (USFDA) has issued an Establishment Inspection Report (EIR) for the manufacturing facility of the Company located at Plot No. L-82 & L-83, Verna Industrial estate, Verna, Goa.
Marksans Pharma Limited headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company’s manufacturing facilities located in India, USA and UK are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA. The company’s product portfolio spreads over major therapeutic segments of CVS, CNS, Anti-diabetic, Pain Management, Gastroenterological and Anti allergies. The company is marketing these products globally.
